Scholar Rock (NASDAQ:SRRK) has announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab. The data showed that continued treatment with apitegromab was associated with substantial and sustained improvement in motor function in patients with nonambulatory Types 2 and 3 spinal muscular atrophy (SMA). The company is progressing with the enrollment in the pivotal Phase 3 SAPPHIRE registrational trial, with completion anticipated in Q3 2023.